Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Author:
Publisher
Elsevier BV
Reference204 articles.
1. Acalabrutinib: a selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies;Abbas,2021
2. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases;Abella;Am. J. Physiol. Endocrinol. Metab.,2009
3. Genomic structure of human FLT3: implications for mutational analysis;Abu-Duhier;Br. J. Haematol.,2001
4. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III;Agnès;Gene,1994
5. Review of the treatment of non-small cell lung cancer with gefitinib;Araki;Clin. Med. Insights Oncol.,2012
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Star wars against leukemia: attacking the clones;Leukemia;2024-09-02
2. Layer-by-layer fabrication of covalent organic frameworks on stainless steel needles as solid-phase microextraction probe coupled with electrospray ionization mass spectrometry for enrichment and determination of tyrosine kinase inhibitors in biosamples;Journal of Chromatography A;2024-09
3. Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes;ACS Medicinal Chemistry Letters;2024-08-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3